Exploitation of transporters to develop novel antimicrobials against Gram-negative bacteria

我们需要新型抗生素，因为耐多药细菌正威胁着我们治疗传染病的能力。英国政府估计，如果没有新的抗生素，到2050年，传染病将使全球经济损失100万亿美元。Discuva的创新（和专有）技术（SATIN）是发现新抗生素的成熟平台；SATIN已经提供了具有新作用机制的新型抗菌化合物，并计划在2017年进行临床试验，用于治疗耐多药淋病。该项目将使用这项英国发明的技术来提供改进的抗生素，这些抗生素对一些最耐药的细菌具有高活性，并且与传统抗生素相比，选择耐药的可能性降低。这将解决与最耐药和危及生命的细菌感染（包括大肠杆菌）相关的临床失败问题。最终，该项目有可能为患者、NHS（以及全球卫生保健系统）和抗生素研究界带来重大利益。

We need new classes of antibiotics because multi-drug resistant (MDR) bacteria are threatening our ability to treat infectious disease. The UK government estimates that without new antibiotics infectious disease will cost the global economy $100 trillion by 2050. Discuva’s innovative (and proprietary) technology (SATIN) is a proven platform for the discovery of new antibiotics; SATIN has already delivered new antibacterial compounds with novel mechanisms-of-action and within our lead programme clinical trials are planned in 2017 for the treatment of MDR gonorrhoea. This project will use this UK invented technology to deliver improved antibiotics which are both highly active against some of the most resistant bacteria causing disease and have a reduced likelihood of selecting resistance compared to conventional antibiotics. This will address the issue of clinical failure associated with the most resistant and life-threatening bacterial infections including E. coli. Ultimately, this project has potential for significant benefits to patients, the NHS (and health care systems globally), and the antibiotc research community.